Showing results (91-100 of 123) with videos related to

Sort By:
Pageof 13
European Journal of Haematology|March 20, 2019
Addressing the room for improvement in management of acute promyelocytic leukemiaJan M Nørgaard, Lone S Friis, Jørgen S Kristensen, et al.
American Journal of Hematology|December 30, 2014
G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasmPamela S Becker, Bruno C Medeiros, Anthony S Stein, et al.
Investigational New Drugs|April 25, 2022
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human studyPatricia LoRusso, Mark J Ratain, Toshihiko Doi, et al.
Blood Advances|February 15, 2019
Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 studyGuillermo Garcia-Manero, Yasmin Abaza, Koichi Takahashi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2021
Plasma Microbial Cell-free DNA Next-generation Sequencing in the Diagnosis and Management of Febrile NeutropeniaEsther Benamu, Kiran Gajurel, Jill N Anderson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid TumorsSara M Tolaney, Khanh T Do, Joseph P Eder, et al.
JAMA Oncology|September 8, 2017
Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of MortalityMohamed L Sorror, Barry E Storer, Amir T Fathi, et al.
Blood|January 31, 2023
Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemiaStephen K Tahir, Emiliano Calvo, Benedito A Carneiro, et al.
Nature Communications|November 25, 2025
Whole-body CD8+ T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 studyJanneke W de Boer, Kylie Keijzer, Jaap A van Doesum, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 9, 2017
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignanciesStephen E Kurtz, Christopher A Eide, Andy Kaempf, et al.
Pageof 13